Adjuvant Nivolumab Beneficial in Esophageal, GE Junction Cancer
A study found that patients with gastroesophageal junction cancer who were treated with surgery and chemoradiotherapy had significantly longer disease-free survival if they then received Opdivo vs. a placebo.
Read Source
